Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone Oncology Opens New State-of-the-Art Personalized Cancer Immunotherapy Manufacturing Facility

November 28, 2017

Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients

October 18, 2017

FierceBiotech Names Gritstone Oncology as a “Fierce 15” Biotechnology Company of 2017

September 26, 2017

Gritstone Oncology Secures $92.7 Million In Series B Financing

September 7, 2017

Gritstone Oncology Expands Scientific Advisory Board with Appointment of Immuno-Oncology Experts James L. Gulley and Alessandro Sette

June 1, 2017

Gritstone Oncology Appoints Raphaël F. Rousseau, M.D., Ph.D., as Chief Medical Officer

May 3, 2017

First Public Data Presented from Gritstone Oncology’s Tumor Antigen Identification Platform for Personalized Cancer Immunotherapy

March 31, 2017

Gritstone Oncology to Present at Cowen and Company’s 37th Annual Health Care Conference

March 1, 2017

Immune Design and Gritstone Oncology Announce Clinical Collaboration for Neoantigen Cancer Immunotherapy

May 9, 2016

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Current page 6

© 2020 Gritstone Oncology |

Footer Links

Privacy Policy
Terms of Use
Contact

socials

Top